Head-to-head · WeighScore
OurView Health vs Teleios Health
The verdict
OurView Health takes it — 67.6/100 to 60.2/100.
OurView Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. OurView (OurView Health) is a 100% online multi-vertical telehealth service with an Our View Savings Club membership offering pharmacy-direct pricing on U.S.-compounded medications.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | OurView Health | Teleios Health |
|---|---|---|
| WeighScore | 67.6/100 | 60.2/100 |
| Grade | C | C |
| Scorecard rank | #162 | #327 |
| Semaglutide | $75/mo (starting dose, compounded) | $99/mo (starting dose, compounded) |
| Tirzepatide | $135/mo (starting dose, compounded) | $139/mo (starting dose, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #162 · C
Strengths
- Low starting prices via the Savings Club — compounded semaglutide from $75, tirzepatide from $135
- Clear product pricing with no contracts; medication shipped to your door (30-day supply)
- Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)
- Discloses meds are compounded by a licensed third-party pharmacy; multi-vertical (TRT, HRT, BHRT, peptides)
Where it loses points
- A comparison table on the site quotes $90 'without membership' against $75 'with membership' while the product cards say 'No membership' and the cart charges $75 without one — the provider contradicts itself on whether a membership exists
- Both figures are starting-dose rates; the cost of a titrated dose is published as a ladder rather than a single price
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #327 · C
Strengths
- Compounded semaglutide from $99/mo — among the lowest floor prices in cash-pay telehealth
- Compounded tirzepatide from a competitive $139/mo floor
- Markets physician (MD/DO) prescribing rather than an NP-only model
- Clean meta-tag and SEO implementation
Where it loses points
- Single-page app: state availability, pharmacy partner, dose pricing, lab requirements, and refund policy aren't visible and couldn't be verified
- No named medical director, physician, or corporate entity disclosed
- Year founded unknown — a newer floor-price entrant warranting extra scrutiny
- No LegitScript, NABP, or SOC 2 trust signal found
- Heavy paid-acquisition ad-tech stack — pair with diligence on the clinical layer
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.